Japan Next-Generation Sequencing (NGS) Services Market (2017-2022)
The Japan Next-Generation Sequencing (NGS) Services Market was valued at $33.3 Million in 2017 and projected to reach to $85.1 Million by 2022, representing a compound annual growth rate of 20.6%. Japan's NGS services market is positioned for sustained growth through 2022 and beyond, supported by the country's commitment to precision medicine and genomic research excellence.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Japan Next-Generation Sequencing (NGS) Services Market Trends and Insights
- In 2017, Japan's NGS services market was valued at $33.3 million, establishing a strong foundation for accelerated growth driven by increased genomic research investments and clinical applications.
- By 2022, Japan's market is forecast to reach $85.1 million, representing a compound annual growth rate of 20.6% and underscoring the nation's commitment to genomic innovation. Japan's NGS services sector benefits from substantial government support for life sciences research, rising prevalence of genetic disorders, and expanding pharmaceutical and biotechnology sectors.
- Japan's aging population and emphasis on personalized healthcare solutions have catalyzed demand for advanced sequencing technologies across diagnostic, research, and therapeutic applications.
- The trajectory from $33.3 million in 2017 to $85.1 million in 2022 positions Japan as a significant contributor to the Asia Pacific NGS services landscape, with continued momentum expected as clinical adoption deepens..
Key Market Statistics
- CAGR (2017-2022) 20.6% CAGR
- Market Size, 2017 ~USD 33.3 Million
- Forecast, 2022 ~USD 85.1 Million
- Country Japan
Japan Next-Generation Sequencing (NGS) Services Market Overview
Rapid Market Expansion :
Japan's NGS services market grew from $33.3 million in 2017 to $85.1 million in 2022, representing a 20.6% CAGR and demonstrating strong market momentum driven by precision medicine adoption.
Advanced Healthcare Infrastructure :
Japan's sophisticated healthcare system and high healthcare spending per capita create an ideal environment for NGS service adoption, with strong institutional support for genomic research initiatives.
Genomic Research Investment :
Increased government and private sector investments in genomic research programs have accelerated NGS service utilization across Japanese research institutions and clinical laboratories.
Clinical Application Growth :
Expanding clinical applications of NGS in oncology, rare disease diagnosis, and personalized medicine are driving demand among Japanese hospitals and diagnostic centers.
Japan Next-Generation Sequencing (NGS) Services Market Dynamics
- The market's 20.6% CAGR reflects increasing adoption among clinical laboratories, research institutions, and pharmaceutical companies seeking advanced sequencing capabilities.
- Japan's aging population and prevalence of genetic disorders create strong demand drivers for NGS-based diagnostics and treatment planning. Future growth will be catalyzed by technological advancements, declining sequencing costs, and expanded reimbursement coverage for NGS-based tests.
- Japanese healthcare providers are increasingly integrating NGS into standard diagnostic protocols, particularly in oncology and rare disease management.
- Continued investment in genomic infrastructure and skilled workforce development will solidify Japan's position as a leading NGS services market in Asia-Pacific..
Market Ecosystem
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The next-generation sequencing services market, valued at US$3.40 billion in 2024, stood at US$3.80 billion in 2025 and is projected to advance at a resilient CAGR of 18.2% from 2025 to 2030, culminating in a forecasted valuation of US$8.77 billion by the end of the period. The global next-generation sequencing services market is growing as sequencing is used more widely in oncology, rare disease diagnostics, infectious disease monitoring, and broader precision medicine initiatives, with healthcare providers and biopharmaceutical companies increasingly outsourcing complex genomic workflows to specialized service partners.
KEY TAKEAWAYS
-
By RegionThe North American next-generation sequencing services market accounted for a 40.8% revenue share in 2024.
-
By OfferingsBy offering, the products segment dominated the next-generation sequencing services market in 2024.
-
By Service typeBy type, the services segment is expected to register the highest CAGR of 18.0%.
-
By End userIn the next-generation sequencing services end user market, the academic & research institutes segment is projected to grow at the fastest rate from 2025 to 2030.
-
By ApplicationBy application, the diagnostics segment is projected to grow at the fastest rate from 2025 to 2030.
-
Competitive LandscapeIllumina, Inc., Thermo Fisher Scientific, and Eurofins Scientific were identified as some of the star players in the North American next-generation sequencing services market, given their strong market share and product footprint.
-
Competitive LandscapeNovogene, Co. Ltd., MedGenome, and Singular Genomics, among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders
The global next-generation sequencing services market continues to grow significantly as a larger number of organizations decide to use sequencing services outside their own facilities to obtain quality genomic data. There is an increasing need for services that facilitate the earlier and more accurate detection of diseases, the selection of appropriate therapies, and the application of translational research, both in clinical and research domains. The speed of the cancer-related application (tumor profiling, MRD, liquid biopsy) usage, as well as rare and inherited diseases testing, reproductive health screening, and infectious disease surveillance, is going up.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The impact on stakeholders of the next-generation sequencing services market is evolving in line with shifting healthcare priorities, rapid advancements in sequencing technologies and analytics, and increasing demand for personalized, data-rich care worldwide. Hospitals and clinical labs, as well as academic and public research centers, and pharmaceutical and biotechnology companies, are the primary customers for outsourced NGS services, which are deployed for oncology, rare disease testing, reproductive health, infectious disease applications, and drug discovery.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Population genomics and pathogen surveillance programs creating steady service volumes
-
Falling sequencing cost and easy access to scalable capacity
Level
-
Uneven reimbursement and limited coverage for clinical sequencing
Level
-
Multi-omics service bundles for drug discovery and translational research
-
Sample-to-report' diagnostic services with interpretation and reanalysis
Level
-
hortage of specialized talent in bioinformatics and clinical interpretation
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Population genomics and pathogen surveillance programs creating steady service volumes
Many countries are funding large genomics and surveillance efforts. These programs require consistent throughput and repeated testing over extended periods. Service providers benefit because they can centralize workflows and scale quickly. This drives recurring demand for sequencing, plus analysis and reporting.
Restraint: Uneven reimbursement and limited coverage for clinical sequencing
Payment pathways still vary widely by country and payer. Hospitals may hesitate to send routine cases when reimbursement is unclear, which slows adoption in diagnostics, even when clinical value is recognized. Service volumes then grow unevenly across regions and indications.
Opportunity: Growth of multi-omics, data analytics, and biopharma collaborations
Clients are increasingly requiring the integration of genomics with transcriptomics and other omics layers. This improves target identification, biomarker work, and patient stratification. Service providers can solve bigger programs by offering one integrated workflow. Demand rises further when analysis, interpretation, and sequencing are included.
Challenge: Shortage of specialized talent in bioinformatics and clinical interpretation
Scaling services needs trained analysts, in addition to sequencing machines. Many regions face gaps in genomics data science and reporting expertise; this can hit turnaround time and create bottlenecks as volumes rise. Providers must invest in training, automation, and standardized pipelines to keep pace.
NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Scientists studying Usutu virus sent viral nucleic acid to Eurofins Genomics for a dedicated RNA-virus sequencing service (INVIEW virus sequencing) on an Illumina NovaSeq 6000 to generate whole-genome data for analysis and comparison with other methods | Quick access to high-quality viral genomes | High-throughput sequencing without adding lab capacity | Supports surveillance and phylogenetics | Clean data for downstream bioinformatics |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The global next-generation sequencing services market environment comprises sequencing service providers, specialty clinical labs, and research-focused genomics partners. These entities perform high-throughput workflows for whole-genome, whole-exome, targeted panels, RNA sequencing, metagenomics, and single-cell projects. A large number of them also offer the services of sample handling, library preparation, QC, bioinformatics, and interpretation, so that customers obtain the most processed results and not just raw data. On the demand side, biopharma companies, CROs, hospitals, reference labs, academic centers, and public health agencies are the primary users. They use service providers as a means to scale their programs in oncology, rare disease testing, reproductive health, infectious disease surveillance, and drug ??????discovery.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
NGS Services Market, By Service type
As of 2024, sequencing services accounted for the largest share of the global next-generation sequencing services market and are expected to remain the leading service type over the next several years. This is driven by steady demand from clinical labs, hospitals, academic centers, and biopharmaceutical companies for scalable access to whole-genome sequencing, whole-exome sequencing, targeted panels, RNA sequencing, and metagenomics without the need to expand in-house capacity.
NGS Services Market, By Workflow
As of 2024, the sequencing step accounted for the largest share of the global next-generation sequencing services market by workflow and is expected to remain the dominant step over the next several years. This is because sequencing is the core value-creating activity that determines data yield, accuracy, turnaround time, and cost per sample. Service providers generate the majority of their workflow revenue by running high-throughput sequencing across WGS, WES, targeted panels, RNA-seq, and metagenomics for clinical and research customers.
NGS Services Market, By Application
As of 2024, the diagnostics sector was the major contributor to the global next-generation sequencing services market in terms of application and is anticipated to maintain its dominance for the following years. A key factor supporting this trend is the fact that clinical users are turning to external sequencing services more and more in order to obtain ready-to-report results without the need to set up large in-house sequencing and bioinformatics teams. The highest demand for diagnostic services is associated with oncology profiling (support for tissue and liquid biopsies), genetic and rare disease testing, reproductive health screening, as well as infectious disease identification and surveillance.
NGS Services Market, By End user
As?????? of 2024, academic & research institutes were the major contributors to the global next-generation sequencing services market by end user and are projected to remain the leading segment during the forecast period. These institutions, universities, and research centers are involved in numerous projects, including whole-genome, whole-exome, RNA-seq, metagenomics, and single-cell studies. To get high-throughput capacity and save on the costs of instruments and staff in their labs, they frequently outsource ??????sequencing.
REGION
Asia Pacific to be the fastest-growing region in the global NGS services market during the forecast period
The next-generation sequencing services market is expected to grow significantly over the forecast period, driven by the expansion of genomics and precision medicine programs across countries such as China, India, Japan, and South Korea. Growth is further propelled by rising biopharmaceutical R&D and clinical trials that rely on NGS-based biomarker discovery, together with a rapidly expanding molecular diagnostics and oncology testing ecosystem and increasing investments in automation, AI-enabled bioinformatics, and cloud-based data platforms to support high-throughput and decentralized sequencing workflows.
NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET: COMPANY EVALUATION MATRIX
In the global next-generation sequencing services matrix, Illumina (Star) is combining a technological ecosystem to capture a large share of the outsourced sequencing capacity globally, which supports its leading position. By using Illumina platforms, service providers and large reference labs carry out high-throughput whole-genome, whole-exome, targeted panel, and RNA sequencing. WuXi Biologics (Emerging Leader) is becoming more prominent on the services side as biopharma customers increasingly seek partners who can provide them with end-to-end development support, along with strong analytical capabilities. Although WuXi Biologics is not a purely sequencing lab, its expanding involvement in biologics development and manufacturing is attracting more demand for sequencing-enabled workflows linked to cell line and clone characterization, genetic stability, and translational support.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Illumina, Inc. (US)
- Thermo Fisher Scientific, Inc. (US)
- Eurofins Scientific (Luxembourg)
- Wuxi Biologics (China)
- Qiagen (Netherlands)
- Revvity (US)
- BGI Group (China)
- Macrogen, Inc. (South Korea)
- Azenta US (US)
- Novogene Co. Ltd (China)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 3.40 Billion |
| Market Forecast in 2030 (Value) | USD 8.78 Billion |
| Growth Rate | CAGR of 18.2% from 2025-2030 |
| Years Considered | 2022-2030 |
| Base Year | 2024 |
| Forecast Period | 2025-2030 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East, Africa |
| Parent & Related Segment Reports |
Next generation Sequencing Market North America Next Generation Sequencing Market Europe Next Generation Sequencing Market Asia Pacific Next Generation Sequencing Market Germany Next Generation Sequencing Market France Next Generation Sequencing Market UK Next-generation Sequencing Market South Korea Next-Generation Sequencing Market China Next Generation Sequencing Market Single-Molecule Real Time (SMRT) Sequencing Market |
WHAT IS IN IT FOR YOU: NEXT-GENERATION SEQUENCING (NGS) SERVICES MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Global NGS service provider / sequencing lab network | Competitive benchmarking of global NGS service providers by service menu (WGS/WES/panels/RNA-seq/metagenomics/single-cell), pricing bands, and turnaround times |
|
| Bioinformatics / software platform company |
|
|
RECENT DEVELOPMENTS
- June 2026: F. Hoffmann-La Roche Ltd. launched AXELIOS 1, a new next-generation sequencing platform powered by Roche’s proprietary Sequencing by Expansion (SBX) technology. The research-use-only system provides single-molecule sequencing with near-real-time analysis and is designed to deliver same-day whole-genome sequencing, combining speed, scalability and flexibility for genomic research.
- May 2026: Illumina, Inc. introduced a new distributed whole-genome sequencing solution for highly sensitive molecular residual disease (MRD) research, built on the NovaSeq X platform. The solution combines whole-genome sequencing with a distributed kit workflow and is designed for solid-tumor MRD and blood-cancer genomic profiling, marking the first offering in Illumina’s new WGS oncology research portfolio
- April 2026: QIAGEN introduced new QIAseq research panels for use on next-generation sequencers, including the QIAseq xHYB HRD Panel and QIAseq xHYB Trinity DNA/RNA Kit. The products expand QIAGEN’s NGS portfolio for genomic profiling, with the Trinity kit supporting comprehensive DNA/RNA profiling on the Element Biosciences AVITI platform while reducing hands-on workflow steps.
- September 2025 : Illumina announced the launch of Illumina Protein Prep, an assay designed for next-generation sequencing (NGS)-based proteomics research. The product enables integration of proteomics into large-scale genomics studies across cancer, cardiometabolic, and immunologic research.
- July 2025 : QIAGEN launched its new QIAseq xHYB Long Read Panels, a set of target enrichment tools designed to support long-read sequencing of complex genomic regions. The panels are optimized for compatibility with native long-read platforms, such as those from PacBio, and are intended to improve detection of a broader range of genomic variations.
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Key Takeaways
- Japan's NGS services market grew from $33.3 million in 2017 to a forecasted $85.1 million in 2022, representing a 20.6% CAGR.
- Japan's advanced healthcare infrastructure and government support for genomic research drive sustained market expansion and clinical adoption.
- Japan's aging population and focus on personalized medicine create strong demand for NGS-based diagnostic and therapeutic applications.
- Japan's position within Asia Pacific positions the country as a key growth hub for next-generation sequencing service providers.
Next-Generation Sequencing (NGS) Services Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2017 |
| Fastest Growing Segment | AGRICULTURE & ANIMAL RESEARCH (Application) |
| Forecast Period | 2017–2022 |
| Growth Rate | CAGR of 21% from 2017 to 2022 |
| Largest Segment | DIAGNOSTICS (Application) |
| Market Size Base Year (Billions) | ~USD 1.06 (2017) |
| Revenue Forecast (Billions) | ~USD 2.748 (2022) |
| Segments Covered | Type, Application, End User, Technology |
Japan Next-Generation Sequencing (NGS) Services Market Report Segmentation
4 segment dimensions are covered across the global market.
By Type
- Chip-Seq
- De Novo Sequencing
- Exome Sequencing
- Methyl-Seq
- Other Ngs Services
- Other Services
- Rna-Seq
- Targeted Sequencing/Custom Gene Panels
- Targeted Sequencing/Gene Panels
- Whole-Genome Sequencing
By Application
- Agriculture & Animal Research
- Biomarker Discovery
- Diagnostics
- Drug Discovery
- Infectious Diseases
- Oncology
- Other Applications
- Other Applications*
- Other Diagnostic Applications
- Rare Genetic Disorders
- Reproductive Health
By End User
- Academic & Government
- Academic & Government Institutes And Research Centers
- Hospitals & Clinics
- Other End Users
- Other End Users*
- Pharmaceutical & Biotechnology Companies
By Technology
- Ion Semiconductor Sequencing
- Nanopore Sequencing
- Sequencing By Synthesis
- Single-Molecule Real-Time Sequencing
Target Audience
- NGS Service Providers : Sequencing companies and diagnostic laboratories need Japan-specific market data to assess market potential, competitive positioning, and expansion strategies in this high-growth Asian market.
- Healthcare Investors : Private equity and venture capital firms require detailed Japan NGS market analysis to evaluate investment opportunities, growth trajectories, and exit potential in the precision medicine sector.
- Pharmaceutical Companies : Drug developers and biotech firms need insights into Japan's NGS adoption rates and clinical applications to inform companion diagnostic strategies and precision medicine initiatives.
- Hospital & Laboratory Administrators : Japanese healthcare facility leaders require market benchmarking data and adoption trends to make informed decisions about NGS service implementation and technology investments.
- Market Research & Consulting Firms : Research organizations need comprehensive Japan NGS market data to support client advisory services, competitive analysis, and strategic planning in the healthcare genomics sector.
Key Companies in the Japan Next-Generation Sequencing (NGS) Services Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ILLUMINA, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| PERKINELMER, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| EUROFINS SCIENTIFIC SE | Luxembourg | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| MACROGEN, INC. | South Korea | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| QIAGEN N.V. | Netherlands | Public Company | Targeted sequencing services (panels, amplicon, gene panels),RNA-Seq services,Exome and de novo sequencing services, |
| DNA LINK, INC. | South Korea | Public Company | Whole genome & De Novo sequencing services,Whole exome & targeted sequencing services,Transcriptome & single-cell RNA sequencing, |
| TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.) | Japan | ||
| NOVOGENE CORPORATION | China | Public Company | Whole genome and targeted sequencing services (incl. human/animal/plant/microbial WGS and targeted panels),Transcriptomics and single-cell sequencing (mRNA, lncRNA, small RNA, single-cell, spatial),De novo, metagenomics, and microbiome sequencing, |
| PERSONALIS, INC. | United States | Public Company | Oncology MRD and monitoring (NeXT Personal, NeXT Personal Dx),Comprehensive tumor profiling (ImmunoID NeXT, NeXT Dx),Population and research sequencing (WES/WGS services), |
ILLUMINA, INC.
Illumina, Inc. is a public company founded in 1998 and headquartered in the United States with 8,625 employees. The company is a leader in DNA sequencing and genetic analysis technologies.
PERKINELMER, INC.
PerkinElmer, Inc. is a public company founded in 1937 and based in the United States with 11,000 employees. The company provides diagnostic and research solutions across life sciences and environmental testing.
EUROFINS SCIENTIFIC SE
Eurofins Scientific SE is a public company founded in 1987 and headquartered in Luxembourg with 65,694 employees. The company operates a network of laboratories providing testing and analytical services across multiple industries.
MACROGEN, INC.
Macrogen, Inc. is a public company founded in 2000 and based in South Korea with 293 employees. The company provides genomic research services including DNA sequencing and analysis.
QIAGEN N.V.
QIAGEN N.V. is a public company founded in 1984 and headquartered in the Netherlands with 5,500 employees. The company develops and manufactures molecular diagnostics and life sciences tools.
DNA LINK, INC.
DNA Link, Inc. is a public company founded in 2000 and based in South Korea with 84 employees. The company offers genomic analysis and genetic testing services.
TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.)
Takara Bio Inc. is a company based in Japan and operates as part of Takara Holding Company Inc. The company specializes in biotechnology and life sciences research products.
NOVOGENE CORPORATION
Novogene Corporation is a public company founded in 2011 and based in China with 2,225 employees. The company provides genomic sequencing and bioinformatics analysis services.
PERSONALIS, INC.
Personalis, Inc. is a public company founded in 2011 and based in the United States with 260 employees. The company develops genomic testing and analysis solutions for precision medicine.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise market valuation data for Japan ($33.3M in 2017, $85.1M in 2022) with verified 20.6% CAGR to support investment decisions and business planning in the Japanese NGS sector.
- Competitive Landscape Intelligence : Understand Japan-specific market dynamics, key players, and competitive positioning to identify partnership opportunities and market entry strategies tailored to the Japanese healthcare ecosystem.
- Clinical Adoption Insights : Access detailed analysis of NGS adoption rates across Japanese hospitals, diagnostic centers, and research institutions to benchmark performance and identify high-growth clinical segments.
- Regulatory & Reimbursement Analysis : Gain comprehensive understanding of Japan's regulatory framework, reimbursement policies, and healthcare system requirements specific to NGS services for compliant market expansion.
- Strategic Growth Opportunities : Identify emerging opportunities in precision oncology, rare disease diagnosis, and personalized medicine within Japan's advanced healthcare market to drive revenue growth and market share expansion.
Frequently asked questions
What was Japan's NGS services market size in 2017?
Japan's NGS services market was valued at $33.3 million in 2017, serving as the baseline for subsequent growth projections.
What is the forecast for Japan's NGS services market in 2022?
Japan's NGS services market is forecast to reach $85.1 million by 2022, reflecting strong market momentum and clinical adoption.
What is the CAGR for Japan's NGS services market?
Japan's NGS services market is projected to grow at a compound annual growth rate of 20.6% between 2017 and 2022.
What factors are driving growth in Japan's NGS services market?
Japan's NGS market growth is driven by government support for genomic research, an aging population, rising genetic disorder prevalence, and increased adoption of personalized medicine approaches.
How does Japan's NGS market compare to the global market?
Japan's NGS services market CAGR of 20.6% aligns closely with the global CAGR of 21%, demonstrating Japan's strong participation in the worldwide genomic services expansion.
RESEARCH METHODOLOGY
Get the Full Next-Generation Sequencing (NGS) Services Market Report
Full forecast, segment splits, and company analysis for all Next-Generation Sequencing (NGS) Services Market.
- Canada Next-Generation Sequencing (NGS) Services Market
- Germany Next-Generation Sequencing (NGS) Services Market
- France Next-Generation Sequencing (NGS) Services Market
- China Next-Generation Sequencing (NGS) Services Market
- India Next-Generation Sequencing (NGS) Services Market
- U.S. Next-Generation Sequencing (NGS) Services Market
- Roe Next-Generation Sequencing (NGS) Services Market
- U.K. Next-Generation Sequencing (NGS) Services Market
- Roapac Next-Generation Sequencing (NGS) Services Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
